Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €134.29 EUR
Change Today +4.98 / 3.85%
Volume 15.0
UTH On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:32 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

united therapeutics corp (UTH) Snapshot

Open
€128.58
Previous Close
€129.31
Day High
€134.29
Day Low
€128.34
52 Week High
04/13/15 - €178.72
52 Week Low
09/4/14 - €84.71
Market Cap
6.1B
Average Volume 10 Days
110.2
EPS TTM
--
Shares Outstanding
45.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UNITED THERAPEUTICS CORP (UTH)

united therapeutics corp (UTH) Related Businessweek News

View More BusinessWeek News

united therapeutics corp (UTH) Details

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

740 Employees
Last Reported Date: 02/24/15
Founded in 1996

united therapeutics corp (UTH) Top Compensated Officers

Founder, Chairman and Co-Chief Executive Offi...
Total Annual Compensation: $1.0M
Co-Chief Executive Officer, President and Dir...
Total Annual Compensation: $840.4K
Executive Vice President of Strategic Plannin...
Total Annual Compensation: $731.0K
Compensation as of Fiscal Year 2014.

united therapeutics corp (UTH) Key Developments

European Commission Grants Marketing Authorisation for United Therapeutics Corporation's Unituxin™ (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma

United Therapeutics Corporation announced that the European Commission (EC) has granted Marketing Authorisation for Unituxin™ (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT). Unituxin is administered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and isotretinoin. The European approval was based on demonstration of improved event-free survival (EFS) and overall survival (OS) in a multicenter, open-label, randomized trial (ANBL0032) sponsored by the US National Cancer Institute under a Cooperative Research and Development Agreement with United Therapeutics and conducted by the Children's Oncology Group (COG). Trial design and results: The trial randomized (1:1) 226 patients to either the Unituxin/13-cis-retinoic acid (RA) arm or the RA alone arm. Patients in each arm received six cycles of treatment. The Unituxin/RA arm consisted of Unituxin in combination with granulocyte macrophage-colony stimulating factor and RA (cycles 1, 3, and 5), Unituxin in combination with interleukin-2 and RA (cycles 2 and 4), and RA (cycle 6). Patients were 11 months to 15 years of age (median age 3.8 years). The major efficacy outcome measure was investigator-assessed EFS, defined as the time from randomization to the first occurrence of relapse, progressive disease, secondary malignancy or death. The primary intent-to-treat analysis found an improvement in EFS associated with dinutuximab immunotherapy plus isotretinoin as compared to isotretinoin alone. The two-year estimates of EFS were 66% among subjects receiving dinutuximab immunotherapy plus isotretinoin as compared with 48% in subjects receiving isotretinoin alone (log-rank test p = 0.033) although this difference did not reach formal statistical significance according to the pre-specified plan for interim analyses. In addition, OS was evaluated with 3 years of follow-up after the EFS analysis as a secondary endpoint with a significant improvement observed among ITT subjects randomly allocated to receive dinutuximab immunotherapy plus isotretinoin as compared with isotretinoin alone. The three-year estimates of OS were 80% compared with 67% among subjects receiving dinutuximab immunotherapy plus isotretinoin and isotretinoin alone, respectively (log-rank test p = 0.0165). Long-term overall survival was evaluated with five years of follow up after the EFS analysis and continued to demonstrate a survival advantage for patients who received dinutuximab immunotherapy compared to those who received isotretinoin alone. The five-year estimates of OS were 74% for dinutuximab immunotherapy compared to 57% for isotretinoin alone (log-rank test p = 0.030). Frequently occurring adverse reactions: The most frequently occurring (more than 30% of patients) adverse reactions reported during the neuroblastoma studies were hypotension (67%), pain (66%), hypersensitivity (56%), pyrexia (53%), urticaria (49%), capillary leak syndrome (45%), anaemia (45%), hypokalaemia (41%), platelet count decreased (40%), hyponatraemia (37%), alanine aminotransferase increased (35%), decreased lymphocyte count (34%) and decreased neutrophil count (31%). Additional adverse reactions characteristic of an allergic response were also reported- including anaphylactic reaction (18%) and bronchospasm (4%). Posology and method of administration: Unituxin is to be administered by intravenous infusion over five courses at a daily dose of 17.5 mg/m2. It is administered on days 4-7 during courses 1, 3 and 5 (each course lasting approximately 24 days) and on days 8-11 during courses 2 and 4 (each course lasting approximately 28 days). The treatment regimen consists of Unituxin, GM-CSF, IL-2, and isotretinoin, administered over six consecutive courses.

United Therapeutics Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

United Therapeutics Corporation reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $347,161,000 compared to $322,802,000 a year ago. Operating income was $171,705,000 compared to $176,320,000 a year ago. Income before income taxes was $168,334,000 compared to $173,033,000 a year ago. Net income was $99,211,000 compared to $111,852,000 a year ago. Diluted net income per share was $1.91 compared to $2.10 a year ago. Non-GAAP earnings were $132,517,000 compared to $118,655,000 a year ago. Diluted Non-GAAP earnings per share were $2.55 compared to $2.23 a year ago. For the six months, the company reported total revenue of $674,665,000 compared to $612,205,000 a year ago. Operating income was $156,879,000 compared to $392,460,000 a year ago. Income before income taxes was $151,542,000 compared to $386,249,000 a year ago. Net income was $82,570,000 compared to $249,376,000 a year ago. Diluted net income per share was $1.57 compared to $4.54 a year ago.

United Therapeutics Seeks Acquisitions

United Therapeutics Corporation (NasdaqGS:UTHR) announced that it has been engaged in active discussions with companies ranging from start-ups to top 10 drug companies looking to either acquire or in-license assets.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UTH:GR €134.29 EUR +4.98

UTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.130.60 CHF +1.70
Alexion Pharmaceuticals Inc $176.24 USD +5.39
Celanese Corp $59.12 USD +0.96
Nippon Shinyaku Co Ltd ¥4,270 JPY 0.00
Vertex Pharmaceuticals Inc $129.00 USD +4.96
View Industry Companies
 

Industry Analysis

UTH

Industry Average

Valuation UTH Industry Range
Price/Earnings 44.2x
Price/Sales 4.9x
Price/Book 6.4x
Price/Cash Flow 38.0x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNITED THERAPEUTICS CORP, please visit www.unither.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.